Natco Pharma Ltd has launched the first licensed generic version of ledipasvir and sofosbuvir combination in Nepal under its brand Hepcinat LP.
This follows a non-exclusive licensing agreement it had inked with Gilead Sciences earlier this year. The agreement is for manufacturing and selling generic versions of Gilead’s chronic hepatitis C medicines, including generic version of its HARVONI brand in India and 100 developing countries.
Announcing the launch, Natco Pharma on Wednesday said the drug is indicated for treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. It is a two drug fixed dose combination product containing 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet and sold globally by Gilead under its Harvoni brand.
Hepcinat LP has been priced at an MRP of Rs.25,000 for a bottle of 28 tablets in Nepal.
